Mushroom Intake and Depression: A Population-Based Study Using Data from the US National Health and Nutrition Examination Survey (NHANES), 2005–2016

Djibril M. Ba,Xiang Gao,Laila Al-Shaar,Joshua Muscat,Vernon Chinchilli,Robert B. Beelman,John P. Richie
DOI: https://doi.org/10.1016/j.jad.2021.07.080
IF: 6.533
2021-01-01
Journal of Affective Disorders
Abstract:Background: Mushrooms contain numerous bioactive compounds that may be associated with reduced anxiety including vitamin B12, nerve growth factor, antioxidants, and anti-inflammatory agents. We hypothesized that mushroom consumption is associated with a lower risk of depression in American adults. Methods: Data from the National Health and Nutrition Examination Survey 2005-2016 was used. Up to two days of 24 h dietary recall were analyzed to assess mushroom intake frequency. Depression was measured using the Patient Health Questionnaire (PHQ-9, score >= 10). We used multivariable logistic regression models, adjusting for potential confounding factors. Results: Among 24,699 participants (mean (SE) age: 45.5 (0.3) years), the weighted prevalence of depression was 5.9%. Mushrooms were consumed by 5.2% of participants. Compared with the lowest tertile of mushroom intake, participants in the middle tertile (median intake = 4.9 g/d, number of cases = 16) had lower odds of depression (adjusted OR = 0.31; 95% confidence interval [CI] 0.16, 0.60) while those in the highest tertile did not differ (median intake = 19.6 g/d, adjusted OR = 0.91; 95% CI: 0.47, 1.78, number of cases = 22) (P-trend = 0.42). Limitations: Cross-sectional data and lack of information on specific types of mushrooms consumed. Conclusion: Mushroom consumers had a lower odd of depression. However, we did not observe a dose-response relationship.
What problem does this paper attempt to address?